Elysium Health   Report issue

For profit Phase 1 Phase 2
Founded: New York NY United States (2014)
Status: No NME R&D (2014)

Organization Overview

First Clinical Trial
2016
NCT02678611
First Marketed Drug
2017
cyproheptadine (periactin)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

ELYSIUM | Elysium Health | Elysium Health, Inc.

Active Ingredients

Marketed Drugs (4)

calcitriol (rocaltrol) (2018)

cyproheptadine (periactin) (2017)

pyridostigmine bromide (mestinon) (2018)

timolol (blocadren) (2019)

Drugs in Phase 2 Trials (2)

nicotinamide (8 trials)

pterostilbene (6 trials)

Drugs in Phase 1 Trials (1)

niacin (2 trials)

Drugs in Other Trials (2)

1-(beta-d-ribofuranosyl)nicotinamide chloride (1 trial)

3,5-dimethoxy-4'-hydroxy-trans-stilbene (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 1)

Wounds and Injuries (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial APIs: 5